☰

3PBIOVIAN S.L.

Integrating a cross-border CDMO

A 500-person CDMO spanning multiple modality platforms and a growing international sponsor base

Industry
Biopharmaceutical CDMO
Headquarters
Pamplona, Spain
Public information as of
January 2026

A4BEE prepared this analysis from publicly available sources. It reflects our own reading of 3PBIOVIAN S.L.'s published strategy and is not endorsed by, or produced in cooperation with, 3PBIOVIAN S.L.. Company website

Strategic priorities

3PBIOVIAN was formed in 2022 through the merger of 3P Biopharmaceuticals (Spain) and Biovian (Finland), creating a 500-person CDMO offering end-to-end services from early development through commercial GMP manufacturing. The Pamplona site specialises in large-scale microbial and mammalian protein production up to 2,000 litres, while the Turku site focuses on advanced therapy medicinal products including viral vectors, plasmid DNA, and cell therapies. The GeneCity expansion at Turku added cleanroom capacity for ATMPs. A Boston commercial office targets US sponsors. Annual revenues are estimated in the EUR 50-70M range.

The merger brought together two organisations with distinct operational histories, quality management systems, and regional workforce cultures. Fifteen years of independent growth created accumulated technological debt across both sites: multiple generations of laboratory and manufacturing equipment, disconnected LIMS and ERP systems, and manual data handoffs between Pamplona process development and Turku quality control. The complexity is compounded by a multi-modality product portfolio — microbial, mammalian, viral vector, cell therapy — each with different regulatory and analytical requirements.

Leadership has identified digital transformation as the mechanism to bridge the cross-border operational gap and achieve the EUR 75M annual sales target. The priorities are a unified data platform that makes the merged entity feel operationally coherent to sponsors, digital manufacturing capabilities that accelerate viral vector production timelines, and a workforce transformation programme that closes the skills gap created by rapid technology adoption.

Challenges we see

  • M&A Integration Digital & Organizational

    Cross-border data fragmentation between Pamplona and Turku

    The merger of Biovian and 3P Biopharmaceuticals brought two established entities with separate IT systems, different LIMS implementations, and incompatible data formats for quality metrics and process development records. Sponsors working across both sites experience two different data environments rather than one unified operation.

    When technology transfer between Pamplona and Turku requires manual re-entry of process parameters and quality results, the time saved by having two complementary sites is partially consumed by reconciliation work. A sponsor expecting coherent cross-site visibility receives two disconnected data sets that must be manually correlated.

  • Labor Shortages Labor

    Scaling specialised talent faster than facility expansion

    3PBIOVIAN operates 2,000-litre mammalian bioreactors, advanced viral vector platforms, and GeneCity ATMP cleanrooms — requiring personnel with skills that take years to develop. The pace of expansion, including the Turku GeneCity ramp-up, means the workforce is growing faster than specialised talent can be recruited and fully trained.

    When facility capacity is added faster than the workforce is developed, the technical knowledge required to operate new equipment safely under GMP conditions sits with too few people. Knowledge concentration in a small number of specialists creates operational risk when those individuals are unavailable.

  • Digital Transformation Digital

    Legacy OT and IT systems resisting Industry 4.0 integration

    Fifteen years of independent growth at both sites produced a layered OT environment: newer bioreactor controllers sitting alongside older PLC generations, laboratory instruments with proprietary data formats, and ERP/LIMS combinations that do not exchange data automatically. The resulting technological debt is a barrier to the real-time data visibility that modern biopharmaceutical manufacturing requires.

    Where legacy OT hardware has no native IP connectivity, installing a digital twin or centralised monitoring platform requires additional hardware and network infrastructure as a prerequisite. The cost and time of that prerequisite work is often underestimated in digital transformation budgets.

  • Supply Chain Energy & Materials

    Supply chain consumable volatility for single-use bioreactor systems

    Bioprocessing operations depend on single-use bioreactor bags, specialised media, and plasmid inputs sourced through global supply chains. Geopolitical disruption, shipping cost fluctuations exceeding 77 percent, and single-source supplier dependencies mean that consumable costs and lead times are harder to predict than the manufacturing schedule assumes.

    When a consumable lead time doubles unexpectedly, the production schedule for a time-sensitive viral vector batch may no longer be achievable without paying premium prices for expedited delivery — squeezing margins on fixed-price contracts.

  • Compliance Regulatory

    GMP certification of GeneCity cleanrooms under FDA and EMA scrutiny

    The GeneCity ATMP facility at Turku requires full GMP certification from both FDA and EMA before commercial supply can begin. The expanded Pamplona installation similarly requires new certification cycles. Each certification requires a complete quality and validation package that is more complex for advanced therapies than for conventional biologics.

    Certification delays for GeneCity cleanrooms directly affect the ability to serve advanced therapy sponsors under commercial supply agreements. Each month of delay is a month without the anticipated revenue contribution from that capacity, and sponsors with clinical timelines cannot wait indefinitely.

Opportunities, by urgency and business impact

Each bubble is one opportunity, numbered to match the list below. Further right means it bites sooner; higher means a bigger effect on the business. A bigger bubble means a bigger implementation effort.

Source: A4BEE analysis of public sources

  1. Cross-site data platform bridging Pamplona and Turku

    3PBIOVIAN operates two geographically distinct locations with complementary but different technical focuses — large-scale protein manufacturing in Spain versus advanced therapies in Finland — with critical process development, quality metrics, and project management data siloed by site.

    Implement an Industrial Data Platform that creates a unified, ontology-based data ecosystem enabling real-time synchronisation of analytical data and manufacturing logs between Pamplona and Turku, providing sponsors a consistent digital experience regardless of processing location.

    • 3PBIOVIAN merger integration roadmap, 2022-2024
    • Turku GeneCity ATMP facility expansion plans

  2. Digital manufacturing and process automation for viral vector production

    Production of viral vectors like AAV is complex, requiring multiple plasmid inputs and sophisticated downstream purification, with traditional adherent culture methods difficult to scale and suspension-based system transitions requiring extensive optimisation and real-time monitoring.

    Use the AAVion and AAViator platforms alongside Digital Manufacturing services to automate upstream processing and incorporate bioprocess simulation, enabling virtual testing of bioreactor parameters before physical execution — reducing optimisation cycles and increasing batch reliability.

    • AAVion and AAViator platform descriptions, 3PBIOVIAN marketing
    • GeneCity facility scope, ATMP production capability

  3. GxP workforce training at pace with technology adoption

    Rapid adoption of new digital technologies and expansion into advanced therapies creates a digital skills gap where staff may lack expertise to operate new systems or maintain compliance in digital-first environments, with traditional classroom training formats running behind real-time operational needs.

    Transition to an AI-augmented learning empowerment model delivering just-in-time content to the manufacturing floor through AR/VR interfaces, ensuring workforce alignment with GMP standards and operational protocols as new equipment comes online at GeneCity and Pamplona.

    • 3PBIOVIAN Campus and academy programme descriptions
    • GeneCity ATMP workforce requirements

  4. Sustainability and energy optimisation across large-scale facilities

    Large-scale biologics production up to 2,000 litres is energy and water-intensive, with the industry under increasing pressure to meet ESG targets while CDMOs must demonstrate sustainable practices to pharmaceutical clients auditing supply chain environmental impact.

    Integrate bioprocess simulation technology and IoT sensors to monitor and optimise energy usage across facilities, while retrofitting legacy systems with smart control boards to extend equipment life and reduce power consumption — building a sustainability evidence base for sponsor ESG reporting.

    • EU ESG reporting requirements for biopharmaceutical supply chains
    • Large-scale biologics energy intensity benchmarks

  5. Digital lab expansion for in-house analytical capacity

    Sponsors face delays and increased risk when analytical testing is outsourced or fragmented across different labs, particularly for high-sensitivity biologics and advanced therapies, while in-house analytical capacity is expensive to maintain and update with state-of-the-art equipment.

    Expand digital lab capabilities to provide sponsors a transparent, real-time view of analytical results by digitising the flow of analytical data from instrument to LIMS — offering high-quality characterisation and stability studies with reduced turnaround times.

    • 3PBIOVIAN analytical services portfolio
    • ATMP characterisation and stability study requirements, FDA/EMA guidance

What we'd propose

  • Enterprise AI

    Cross-Site Industrial Data Platform for 3PBIOVIAN

    We deploy an ontology-driven industrial data platform that harmonises operational and quality data across the Pamplona and Turku manufacturing sites — enabling real-time cross-site visibility, predictive analytics, and auditable technology transfer that makes the merged entity operate as one coherent CDMO for sponsors.

    • Unified data ontology across sites

      Pamplona and Turku data in one model

      Develop a common data ontology that maps process parameters, quality metrics, and equipment data from both sites into a unified schema — so that a sponsor portal shows a single, coherent view of a project's status across both locations rather than two disconnected data environments.

    • Real-time technology transfer workflow

      Process knowledge transferred with full traceability

      Build a digital technology transfer workflow that captures process development data from Pamplona and makes it immediately available in Turku's quality management system with full audit trail — eliminating the manual re-entry that currently consumes transfer timeline.

    • Sponsor portal with cross-site visibility

      Sponsors see one project view across both sites

      Deliver a sponsor-facing portal that aggregates project status, quality reports, and batch records from both sites into a single dashboard, so that a US sponsor working with Boston office can see the same real-time picture as the Turku site team.

    • The merger begins to feel operationally coherent to sponsors within six months of platform go-live, rather than requiring them to manage two relationships simultaneously.
    • Technology transfer timelines between sites are reduced by eliminating the manual data re-entry step — process knowledge travels at the speed of the network rather than the speed of a technician's typing.
    • A unified quality data model is the prerequisite for consistent GMP documentation across both sites, reducing the validation burden for regulatory submissions.

    We've done this before

    See how we do Enterprise AI
  • Digital CDMO

    Digital Manufacturing and Process Automation for Viral Vector Production

    We implement Digital Manufacturing services alongside the AAVion and AAViator platforms to automate upstream bioprocess control, incorporate real-time process analytics, and deploy a bioprocess simulation environment that reduces the number of physical optimisation runs required before a new suspension cell line delivers its target yield.

    • Bioprocess simulation for AAV production

      Virtual runs before physical execution

      Build a calibrated bioprocess simulation of the AAVion production workflow — including plasmid transfection kinetics, cell culture dynamics, and downstream purification recovery — so that operators can test parameter changes in simulation before committing to a physical run that consumes expensive reagents.

    • Real-time process analytics for suspension cell culture

      Metabolic shifts detected before they affect yield

      Deploy soft sensors and PAT (Process Analytical Technology) tools for real-time monitoring of key cell culture parameters — glucose consumption rate, lactate profiles, cell viability trajectories — giving operators a steering window before metabolic shift becomes irreversible.

    • Downstream purification optimisation

      AI-guided chromatography parameter selection

      Implement a machine learning model trained on historical purification runs to recommend chromatography loadings and gradient profiles for new AAV product types, reducing the empirical screening work required to establish a new purification process.

    • Physical AAV optimisation runs are reduced because simulation identifies viable parameter windows before the bench work begins — each avoided failed run saves reagent costs and shortens the development timeline.
    • Real-time metabolic monitoring gives operators hours of advance warning before a culture shift becomes irreversible, preserving batch yield that would otherwise be lost.
    • The AI-guided purification model improves with every completed run, making each new AAV product type faster to establish than the last.

    We've done this before

    See how we do Digital CDMO
  • Digital Lab

    Digital Lab and Analytical Automation for ATMP Characterisation

    We integrate advanced laboratory equipment — HPLC, qPCR, cell-based potency assays — into a secure, paperless digital environment using LIMS integration and electronic lab notebook capabilities, accelerating characterisation and quality control turnaround times for sponsors across both modalities.

    • LIMS and ELN integration for paperless labs

      Instruments connected to a single digital record

      Integrate laboratory instruments across Pamplona and Turku into a unified LIMS/ELN environment, so that HPLC runs, qPCR data, and potency assay results flow directly into the sample record without manual transcription — eliminating transcription errors and speeding up the quality review cycle.

    • In-line PAT for cell therapy release assays

      Real-time potency data replacing end-point testing

      Deploy in-line or at-line PAT methods for cell therapy product release that reduce the turnaround time from batch completion to quality release certificate — critical for autologous therapies where the patient is waiting.

    • Digital stability study management

      Stability data tracked automatically over time

      Implement a digital stability study management module within the LIMS that automatically schedules sample pull points, tracks storage conditions, and generates stability reports in the required regulatory format — reducing the administrative burden of managing multi-year stability programmes.

    • Analytical turnaround times are reduced because instrument data flows automatically into the LIMS rather than waiting for manual upload — the QC team's time shifts from data entry to data review.
    • Autologous cell therapy release timelines are shortened by in-line potency methods, reducing the window where the finished product is stored while awaiting quality clearance.
    • Stability study documentation is generated automatically, reducing the regulatory submission preparation effort when a product moves from clinical to commercial phase.

    We've done this before

    See how we do Digital Lab
  • Digital Lab

    AI-Augmented Workforce Training for GMP Compliance

    We deploy immersive and AI-driven training solutions — including VR-based GMP procedure practice, AI tutoring for complex equipment operation, and AR-guided shop floor workflows — to upskill the workforce across the merged organisation at a pace that matches the GeneCity and Pamplona expansion timelines.

    • VR-based GMP procedure training

      Practice complex procedures without touching equipment

      Build a library of VR training scenarios covering the GMP procedures that carry the highest error risk — cell culture inoculation, bioreactor sampling, chromatography column packing — allowing operators to practice without consuming production time or risking a GMP deviation on the production equipment.

    • AI tutoring for ATMP equipment operation

      Just-in-time guidance at the equipment

      Deploy an AI tutoring layer on top of GeneCity's advanced therapy equipment that delivers contextual just-in-time guidance to operators based on the current step in the SOP — reducing the time required to achieve independent competency on new equipment types.

    • AR-guided shop floor workflows

      Expert guidance overlaid on the work

      Integrate an assisted-reality layer (RealWear or equivalent) for complex maintenance and calibration procedures at both sites, enabling a senior technician to provide step-by-step visual guidance to a junior colleague from a remote location — scaling expertise without requiring physical co-location.

    • New operators reach independent competency faster because VR practice builds procedural memory before they touch production equipment — the gap between classroom training and operational readiness shrinks.
    • GMP deviations caused by procedural error are reduced when operators have had immersive practice on the specific procedure before performing it under production conditions.
    • Training programme completion rates improve because AR and VR formats are more engaging than classroom slides for procedural content, particularly for a workforce that spans two countries and two language environments.

    We've done this before

    See how we do Digital Lab
  • Digital CDMO

    Sustainability and Energy Optimisation for Large-Scale Biomanufacturing

    We implement IoT-based environmental monitoring and smart control systems across Pamplona and Turku to optimise energy consumption, reduce water usage, and build an automated sustainability data evidence base that supports 3PBIOVIAN's ESG commitments and sponsor audit requirements.

    • IoT energy monitoring across bioprocess equipment

      Every energy consumer tracked in real time

      Install sub-metering IoT sensors on the major energy consumers at both sites — bioreactor heating and cooling loops, HVAC systems, freeze dryer units — to generate a real-time energy map that identifies optimisation opportunities and provides the data foundation for sustainability reporting.

    • Bioprocess simulation for energy efficiency

      Low-energy parameter windows identified in simulation

      Extend the bioprocess simulation capability to include energy consumption as an output variable, so that process development teams can identify the parameter combinations that deliver target yield with minimum energy input before running at production scale.

    • ESG reporting automation

      Sponsor ESG questionnaire responses auto-populated

      Connect the energy monitoring data to a sustainability analytics dashboard that auto-populates the environmental data fields required by pharmaceutical sponsor ESG questionnaires — covering Scope 1 and 2 emissions, water consumption, and waste generation per production batch.

    • Energy consumption per gram of product is reduced because real-time monitoring reveals waste streams — such as persistent cooling demand in empty incubators — that were previously invisible.
    • Sponsor ESG audit responses are produced in minutes rather than days because the data is already structured and tracked rather than estimated from utility bills.
    • The sustainability evidence base supports 3PBIOVIAN's differentiation positioning with pharmaceutical sponsors who face their own Scope 3 emissions reporting requirements.

    We've done this before

    See how we do Digital CDMO

Digital maturity: today and target

Scored out of 100 across six dimensions. The target is what 3PBIOVIAN S.L.'s own published ambition implies — not a perfect score.

Source: A4BEE analysis of public sources
Cross-Site Interoperability 40 → 90
Pamplona and Turku operate separate LIMS, separate ERP systems, and incompatible data formats for process and quality records. A sponsor working across both sites receives two disconnected data sets rather than one unified view — the merger has yet to be made operationally coherent at the data layer.
Digital Twin Capability 30 → 85
No operational bioprocess simulation model exists for the AAVion or AAViator platforms. Process development still relies on physical optimisation runs, which are expensive in reagents and time, particularly for new suspension cell lines that have not yet established a defined operating window.
Analytical Data Automation 55 → 95
Laboratory instruments at both sites are partially connected to LIMS; some data paths require manual transcription. The gap between instrument and record is where transcription errors enter the quality system, and where the QC team spends time on data entry rather than data review.
Production Agility via MTP 35 → 80
The multi-modality product portfolio — microbial, mammalian, viral vector, cell therapy — requires frequent product changeover and equipment reconfiguration. Without MTP-standardised equipment descriptions, each changeover requires a custom engineering intervention rather than a software-mediated reconfiguration.
AI-Augmented Training 65 → 95
The 3PBIOVIAN Campus and academy structure provides a training governance framework, but the delivery mechanisms are primarily classroom-based and slide-driven. AI-augmented and immersive training formats have not yet been deployed at scale, leaving the GeneCity ramp-up dependent on conventional training timelines.
Sustainability Monitoring 45 → 90
Energy and water consumption at both sites is tracked through utility billing rather than sub-metering, providing batch-level or facility-level totals but not the granularity needed to identify specific optimisation opportunities or generate per-batch ESG evidence for sponsors.

Check this yourself

Our Service Portal has free self-assessments and market comparisons. These are the ones that line up with what we've read above — no sales call required.

Think we've read this right?

Talk to us

Related reading

This is an independent analysis prepared by A4BEE from publicly available information as of January 2026. It reflects A4BEE's own interpretation and opinion, is not affiliated with, endorsed by, or verified with 3PBIOVIAN S.L., and may be incomplete or inaccurate. All company names and trademarks are the property of their respective owners. To request a correction or removal, contact [email protected].